Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ADXNBullishCorporate Developmentsnews

High materiality7/10

Addex regains global rights to GABAB PAM assets from Indivior

Sep 25, 2026, 1:15 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The return of control over GABAB PAM assets de-risks a collaboration termination, expands ADXN's portfolio, and creates optionality for licensing deals or standalone development. Historically, rights reversion events in biotech can re-rate valuations as investors anticipate monetization potential.

AI summary

What happened, with direct paths to the underlying reporting

Addex Therapeutics has regained full global rights to its GABAB PAM assets from Indivior after Indivior's R&D rationalization and planned merger with Supernus. The move gives Addex ownership of a broad portfolio targeting GABAB signaling, including a candidate for substance use disorders and a chronic cough program, enabling standalone development or partnerships. The catalysts could unlock licensing deals or in-house advancement.

Addex regains global rights to all GABAB PAM assets from Indivior.
Indivior rationalized R&D and plans to merge with Supernus; assets returned.
Returned asset broadens Addex's GABAB portfolio for substance use and chronic cough.
Addex may pursue new partnerships or advance programs in parallel.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Addex regains global rights to GABAB PAM assets from Indivior

Crude Oil Dips; Addex Therapeutics Shares Spike Higher